Prolactin-Stat5 signaling in breast cancer is potently disrupted by acidosis within the tumor microenvironment

Breast Cancer Research

Hallgeir Rui¹  Craig D Shriver⁵  Jeffrey A Hooke⁵  Albert J Kovatich⁴  Terry Hyslop²  Inna Chervoneva²  Boris Freydin²  Takemi Tanaka⁶  Fransiscus E Utama³  Thai H Tran³  Alicia F Yanac³  Melanie A Girondo³  Amy R Peck³  Chengbao Liu³  Ning Yang³ 

[1] Department of Cancer Biology, Thomas Jefferson University, 233 South 10th Street, BLSB 330, Philadelphia, PA 19107, USA;Department of Pharmacology and Experimental Therapeutics, Division of Biostatistics, Thomas Jefferson University, 1015 Chestnut Street, Philadelphia, PA 19107, USA;Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107, USA;MDR Global Systems, LLC, 425 Park Place, Windber, PA 15963, USA;Department of Surgery, Walter Reed National Military Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20814, USA;Department of Pharmaceutical Sciences, Thomas Jefferson University, Jefferson School of Pharmacy, 130 South 9th Street, Philadelphia, PA 19107, USA

关键词: Stat5;    Prolactin receptor;    Prolactin;    Tumor microenvironment;    Extracellular acidosis;    Breast cancer;   

Others  :  793718
DOI  :  10.1186/bcr3467

 received in 2013-04-11, accepted in 2013-07-12,  发布年份 2013

【 摘 要 】

Introduction

Emerging evidence in estrogen receptor-positive breast cancer supports the notion that prolactin-Stat5 signaling promotes survival and maintenance of differentiated luminal cells, and loss of nuclear tyrosine phosphorylated Stat5 (Nuc-pYStat5) in clinical breast cancer is associated with increased risk of antiestrogen therapy failure. However, the molecular mechanisms underlying loss of Nuc-pYStat5 in breast cancer remain poorly defined.

Methods

We investigated whether moderate extracellular acidosis of pH 6.5 to 6.9 frequently observed in breast cancer inhibits prolactin-Stat5 signaling, using in vitro and in vivo experimental approaches combined with quantitative immunofluorescence protein analyses to interrogate archival breast cancer specimens.

Results

Moderate acidosis at pH 6.8 potently disrupted signaling by receptors for prolactin but not epidermal growth factor, oncostatin M, IGF1, FGF or growth hormone. In breast cancer specimens there was mutually exclusive expression of Nuc-pYStat5 and GLUT1, a glucose transporter upregulated in glycolysis-dependent carcinoma cells and an indirect marker of lactacidosis. Mutually exclusive expression of GLUT1 and Nuc-pYStat5 occurred globally or regionally within tumors, consistent with global or regional acidosis. All prolactin-induced signals and transcripts were suppressed by acidosis, and the acidosis effect was rapid and immediately reversible, supporting a mechanism of acidosis disruption of prolactin binding to receptor. T47D breast cancer xenotransplants in mice displayed variable acidosis (pH 6.5 to 6.9) and tumor regions with elevated GLUT1 displayed resistance to exogenous prolactin despite unaltered levels of prolactin receptors and Stat5.

Conclusions

Moderate extracellular acidosis effectively blocks prolactin signaling in breast cancer. We propose that acidosis-induced prolactin resistance represents a previously unrecognized mechanism by which breast cancer cells may escape homeostatic control.

【 授权许可】

   
2013 Yang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Gillies RJ, Verduzco D, Gatenby RA: Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat Rev Cancer 2012, 12:487-493.
• [2]Zhang X, Lin Y, Gillies RJ: Tumor pH and its measurement. J Nucl Cardiol 2010, 51:1167-1170.
• [3]Wike-Hooley JL, van den Berg AP, van der Zee J, Reinhold HS: Human tumour pH and its variation. Eur J Cancer Clin Oncol 1985, 21:785-791.
• [4]Engin K, Leeper DB, Cater JR, Thistlethwaite AJ, Tupchong L, McFarlane JD: Extracellular pH distribution in human tumours. Int J Hyperthermia 1995, 11:211-216.
• [5]Montcourrier P, Silver I, Farnoud R, Bird I, Rochefort H: Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis 1997, 15:382-392.
• [6]Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP: The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8:3984-4001.
• [7]Chen KH, Tung PY, Wu JC, Chen Y, Chen PC, Huang SH, Wang SM: An acidic extracellular pH induces Src kinase-dependent loss of beta-catenin from the adherens junction. Cancer Lett 2008, 267:37-48.
• [8]Gatenby RA, Gawlinski ET, Gmitro AF, Kaylor B, Gillies RJ: Acid-mediated tumor invasion: a multidisciplinary study. Cancer Res 2006, 66:5216-5223.
• [9]Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R, Krause SW, Kreutz M: Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood 2007, 109:3812-3819.
• [10]Rofstad EK, Mathiesen B, Kindem K, Galappathi K: Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006, 66:6699-6707.
• [11]Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ: Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 2009, 69:2260-2268.
• [12]Walenta S, Salameh A, Lyng H, Evensen JF, Mitze M, Rofstad EK, Mueller-Klieser W: Correlation of high lactate levels in head and neck tumors with incidence of metastasis. Am J Pathol 1997, 150:409-415.
• [13]Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK, Mueller-Klieser W: High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res 2000, 60:916-921.
• [14]Arendt LM, Rugowski DE, Grafwallner-Huseth TA, Garcia-Barchino MJ, Rui H, Schuler LA: Prolactin-induced mouse mammary carcinomas model estrogen resistant luminal breast cancer. Breast Cancer Res 2011, 13:R11. BioMed Central Full Text
• [15]Wennbo H, Gebre-Medhin M, Gritli-Linde A, Ohlsson C, Isaksson OG, Tornell J: Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest 1997, 100:2744-2751.
• [16]Tworoger SS, Eliassen AH, Sluss P, Hankinson SE: A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007, 25:1482-1488.
• [17]Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L: Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc Natl Acad Sci USA 1995, 92:8831-8835.
• [18]Nevalainen MT, Xie J, Bubendorf L, Wagner KU, Rui H: Basal activation of transcription factor signal transducer and activator of transcription (Stat5) in nonpregnant mouse and human breast epithelium. Mol Endocrinol 2002, 16:1108-1124.
• [19]Walker SR, Xiang M, Frank DA: Distinct roles of STAT3 and STAT5 in the pathogenesis and targeted therapy of breast cancer. Mol Cell Endocrinol 2013, S0303-7207. doi:10.1016/j.mce.2013.03.010. Epub ahead of print
• [20]Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H: Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 2005, 24:746-760.
• [21]Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S: Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006, 66:1824-1832.
• [22]Sultan AS, Brim H, Sherif ZA: Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition. Cancer Sci 2008, 99:272-279.
• [23]Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H: Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression. Oncogene 2013. doi:10.1038/onc.2013.172. Epub ahead of print
• [24]Axlund SD, Yoo BH, Rosen RB, Schaack J, Kabos P, Labarbera DV, Sartorius CA: Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties. Horm Cancer 2013, 4:36-49.
• [25]Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA: Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc Natl Acad Sci USA 2008, 105:5774-5779.
• [26]Kabos P, Haughian JM, Wang X, Dye WW, Finlayson C, Elias A, Horwitz KB, Sartorius CA: Cytokeratin 5 positive cells represent a steroid receptor negative and therapy resistant subpopulation in luminal breast cancers. Breast Cancer Res Treat 2011, 128:45-55.
• [27]Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J, Sauter G, Rui H: Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol 2004, 22:2053-2060.
• [28]Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H: Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer. Endocr Relat Cancer 2006, 13:885-893.
• [29]Peck AR, Witkiewicz AK, Liu C, Stringer GA, Klimowicz AC, Pequignot E, Freydin B, Tran TH, Yang N, Rosenberg AL, Hooke JA, Kovatich AJ, Nevalainen MT, Shriver CD, Hyslop T, Sauter G, Rimm DL, Magliocco AM, Rui H: Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 2011, 29:2448-2458.
• [30]Peck AR, Witkiewicz AK, Liu C, Klimowicz AC, Stringer GA, Pequignot E, Freydin B, Yang N, Ertel A, Tran TH, Girondo MA, Rosenberg AL, Hooke JA, Kovatich AJ, Shriver CD, Rimm DL, Magliocco AM, Hyslop T, Rui H: Low levels of Stat5a protein in breast cancer are associated with tumor progression and unfavorable clinical outcomes. Breast Cancer Res 2012, 14:R130. BioMed Central Full Text
• [31]Wagner KU, Rui H: Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 2008, 13:93-103.
• [32]Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME: The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry 2007, 46:2398-2410.
• [33]Kulkarni MV, Tettamanzi MC, Murphy JW, Keeler C, Myszka DG, Chayen NE, Lolis EJ, Hodsdon ME: Two independent histidines, one in human prolactin and one in its receptor, are critical for pH-dependent receptor recognition and activation. J Biol Chem 2010, 285:38524-38533.
• [34]Hansen MJ, Olsen JG, Bernichtein S, O’Shea C, Sigurskjold BW, Goffin V, Kragelund BB: Development of prolactin receptor antagonists with reduced pH-dependence of receptor binding. J Mol Recognit 2011, 24:533-547.
• [35]Neilson LM, Zhu J, Xie J, Malabarba MG, Sakamoto K, Wagner KU, Kirken RA, Rui H: Coactivation of janus tyrosine kinase (Jak)1 positively modulates prolactin-Jak2 signaling in breast cancer: recruitment of ERK and signal transducer and activator of transcription (Stat)3 and enhancement of Akt and Stat5a/b pathways. Mol Endocrinol 2007, 21:2218-2232.
• [36]Utama FE, LeBaron MJ, Neilson LM, Sultan AS, Parlow AF, Wagner KU, Rui H: Human prolactin receptors are insensitive to mouse prolactin: implications for xenotransplant modeling of human breast cancer in mice. J Endocrinol 2006, 188:589-601.
• [37]LeBaron MJ, Crismon HR, Utama FE, Neilson LM, Sultan AS, Johnson KJ, Andersson EC, Rui H: Ultrahigh density microarrays of solid samples. Nat Methods 2005, 2:511-513.
• [38]Tran TH, Utama FE, Lin J, Yang N, Sjolund AB, Ryder A, Johnson KJ, Neilson LM, Liu C, Brill KL, Rosenberg AL, Witkiewicz AK, Rui H: Prolactin inhibits BCL6 expression in breast cancer through a Stat5a-dependent mechanism. Cancer Res 2010, 70:1711-1721.
• [39]http://www.R-project.org
• [40]Brown RS, Goodman TM, Zasadny KR, Greenson JK, Wahl RL: Expression of hexokinase II and Glut-1 in untreated human breast cancer. Nucl Med Biol 2002, 29:443-453.
• [41]Teilum K, Hoch JC, Goffin V, Kinet S, Martial JA, Kragelund BB: Solution structure of human prolactin. J Mol Biol 2005, 351:810-823.
• [42]Zhang X, Mehta RG, Lantvit DD, Coschigano KT, Kopchick JJ, Green JE, Hedayat S, Christov KT, Ray VH, Unterman TG, Swanson SM: Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis 2007, 28:143-150.
• [43]Brunet-Dunand SE, Vouyovitch C, Araneda S, Pandey V, Vidal LJ, Print C, Mertani HC, Lobie PE, Perry JK: Autocrine human growth hormone promotes tumor angiogenesis in mammary carcinoma. Endocrinology 2009, 150:1341-1352.
• [44]Cunningham BC, Bass S, Fuh G, Wells JA: Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science 1990, 250:1709-1712.
• [45]Breskin MW, Worthington-Roberts BS, Knopp RH, Brown Z, Plovie B, Mottet NK, Mills JL: First trimester serum zinc concentrations in human pregnancy. Am J Clin Nutr 1983, 38:943-953.
• [46]Johnson KJ, Peck AR, Liu C, Tran TH, Utama FE, Sjolund AB, Schaber JD, Witkiewicz AK, Rui H: PTP1B suppresses prolactin activation of Stat5 in breast cancer cells. Am J Pathol 2010, 177:2971-2983.
• [47]Jones RG, Thompson CB: Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 2009, 23:537-548.
• [48]Brauer HA, Makowski L, Hoadley KA, Casbas-Hernandez P, Lang LJ, Roman-Perez E, D’Arcy M, Freemerman AJ, Perou CM, Troester MA: Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clin Cancer Res 2013, 19:571-585.
• [49]Keeler C, Tettamanzi MC, Meshack S, Hodsdon ME: Contribution of individual histidines to the global stability of human prolactin. Protein Sci 2009, 18:909-920.
• [50]Cunningham BC, Wells JA: Comparison of a structural and a functional epitope. J Mol Biol 1993, 234:554-563.
• [51]Chawla RK, Parks JS, Rudman D: Structural variants of human growth hormone: biochemical, genetic, and clinical aspects. Annu Rev Med 1983, 34:519-547.
• [52]Somers W, Ultsch M, De Vos AM, Kossiakoff AA: The X-ray structure of a growth hormone-prolactin receptor complex. Nature 1994, 372:478-481.
• [53]Xu J, Zhang Y, Berry PA, Jiang J, Lobie PE, Langenheim JF, Chen WY, Frank SJ: Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex. Mol Endocrinol 2011, 25:597-610.
• [54]Kline JB, Roehrs H, Clevenger CV: Functional characterization of the intermediate isoform of the human prolactin receptor. J Biol Chem 1999, 274:35461-35468.
• [55]Piwnica D, Touraine P, Struman I, Tabruyn S, Bolbach G, Clapp C, Martial JA, Kelly PA, Goffin V: Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. Mol Endocrinol 2004, 18:2522-2542.
• [56]Takenouchi T, Iwamaru Y, Sugama S, Tsukimoto M, Fujita M, Sekigawa A, Sekiyama K, Sato M, Kojima S, Conti B, Hashimoto M, Kitani H: The activation of P2X7 receptor induces cathepsin D-dependent production of a 20-kDa form of IL-1beta under acidic extracellular pH in LPS-primed microglial cells. J Neurochem 2011, 117:712-723.
• [57]Damiano JS, Rendahl KG, Karim C, Embry MG, Ghoddusi M, Holash J, Fanidi A, Abrams TJ, Abraham JA: Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther 2013, 12:295-305.
• [58]Damiano JS, Wasserman E: Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin Cancer Res 2013, 19:1644-1650.